Our Team

Success depends on the right combination of expertise and experience. Our project teams are hand-picked to meet your needs.

Judy Ashworth, MD

Senior Scientific Advisor

Guiding the clinical development of CNS-active drugs in a challenging and rapidly evolving regulatory environment

Jack Henningfield, PhD

Vice President, Research, Health Policy, and Abuse Liability

Leading development and regulatory strategy for new treatments for neurological and psychiatric disorders with high unmet needs

Marion Coe, PhD

Director, Clinical Development and Postmarketing Surveillance

Helping plan optimal pathways for the clinical development and postmarketing surveillance of unique and challenging classes of drugs

Ryan Lanier, PhD

Director, Clinical Development and Abuse Liability

Utilizing extensive clinical and nonclinical research experience to strategically guide the development of new CNS-active drugs

Michelle Ertischek, MPH

Director, Planning and Operations

Sustaining the links between clients and our dedicated project teams

Caitlyn Durgin, MS

Supporting the abuse potential assessment, clinical development and post-marketing surveillance of CNS-active drugs.

Marilyn Huestis, PhD

Senior Advisor, Clinical Pharmacology and Toxicology, Cannabinoid and Other CNS-Active Pharmacotherapies

Applying excellence in clinical and forensic toxicology to CNS-active drug and compound development and regulatory pathways

Speak to an expert.